Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome

a prospective evaluation of 669 patients.

S. Jones, G. Clark, S. Koleszar, G. Ethington, R. Mennel, S. Paulson, B. Brooks, R. Kerr, C. Denham, M. Savin, C. White, J. Blum, R. Kirby, M. Stone, J. Pippen, L. Kitchens, T. George, B. Cooper, G. Peters, S. Knox & 7 others M. Grant, H. Cheek, R. Jones, J. Kuhn, Z. Lieberman, D. Savino, C. Rietz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)310-314
Number of pages5
JournalClinical Breast Cancer
Volume1
Issue number4
StatePublished - Jan 1 2001

Fingerprint

Disease-Free Survival
Breast Neoplasms
S Phase
Neoplasms
Tamoxifen
Doxorubicin
Cyclophosphamide
Statistical Factor Analysis
Flow Cytometry
Therapeutics
Lymph Nodes
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jones, S., Clark, G., Koleszar, S., Ethington, G., Mennel, R., Paulson, S., ... Rietz, C. (2001). Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients. Clinical Breast Cancer, 1(4), 310-314.

Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome : a prospective evaluation of 669 patients. / Jones, S.; Clark, G.; Koleszar, S.; Ethington, G.; Mennel, R.; Paulson, S.; Brooks, B.; Kerr, R.; Denham, C.; Savin, M.; White, C.; Blum, J.; Kirby, R.; Stone, M.; Pippen, J.; Kitchens, L.; George, T.; Cooper, B.; Peters, G.; Knox, S.; Grant, M.; Cheek, H.; Jones, R.; Kuhn, J.; Lieberman, Z.; Savino, D.; Rietz, C.

In: Clinical Breast Cancer, Vol. 1, No. 4, 01.01.2001, p. 310-314.

Research output: Contribution to journalArticle

Jones, S, Clark, G, Koleszar, S, Ethington, G, Mennel, R, Paulson, S, Brooks, B, Kerr, R, Denham, C, Savin, M, White, C, Blum, J, Kirby, R, Stone, M, Pippen, J, Kitchens, L, George, T, Cooper, B, Peters, G, Knox, S, Grant, M, Cheek, H, Jones, R, Kuhn, J, Lieberman, Z, Savino, D & Rietz, C 2001, 'Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.', Clinical Breast Cancer, vol. 1, no. 4, pp. 310-314.
Jones, S. ; Clark, G. ; Koleszar, S. ; Ethington, G. ; Mennel, R. ; Paulson, S. ; Brooks, B. ; Kerr, R. ; Denham, C. ; Savin, M. ; White, C. ; Blum, J. ; Kirby, R. ; Stone, M. ; Pippen, J. ; Kitchens, L. ; George, T. ; Cooper, B. ; Peters, G. ; Knox, S. ; Grant, M. ; Cheek, H. ; Jones, R. ; Kuhn, J. ; Lieberman, Z. ; Savino, D. ; Rietz, C. / Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome : a prospective evaluation of 669 patients. In: Clinical Breast Cancer. 2001 ; Vol. 1, No. 4. pp. 310-314.
@article{b26a762f3e8845d6be23067e5fad3533,
title = "Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.",
abstract = "This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94{\%} and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95{\%} DFS), tamoxifen (441 patients, 94{\%} DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92{\%} DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96{\%} for T1N0 cancer versus 89{\%} for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.",
author = "S. Jones and G. Clark and S. Koleszar and G. Ethington and R. Mennel and S. Paulson and B. Brooks and R. Kerr and C. Denham and M. Savin and C. White and J. Blum and R. Kirby and M. Stone and J. Pippen and L. Kitchens and T. George and B. Cooper and G. Peters and S. Knox and M. Grant and H. Cheek and R. Jones and J. Kuhn and Z. Lieberman and D. Savino and C. Rietz",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "310--314",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome

T2 - a prospective evaluation of 669 patients.

AU - Jones, S.

AU - Clark, G.

AU - Koleszar, S.

AU - Ethington, G.

AU - Mennel, R.

AU - Paulson, S.

AU - Brooks, B.

AU - Kerr, R.

AU - Denham, C.

AU - Savin, M.

AU - White, C.

AU - Blum, J.

AU - Kirby, R.

AU - Stone, M.

AU - Pippen, J.

AU - Kitchens, L.

AU - George, T.

AU - Cooper, B.

AU - Peters, G.

AU - Knox, S.

AU - Grant, M.

AU - Cheek, H.

AU - Jones, R.

AU - Kuhn, J.

AU - Lieberman, Z.

AU - Savino, D.

AU - Rietz, C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.

AB - This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035240070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035240070&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 310

EP - 314

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -